Ischemic Heart Disease Drugs Market Report and Forecast 2025-2034
Description
The ischemic heart disease drugs market was valued at USD 4.94 Billion in 2024, driven by the rising incidence of heart diseases across the globe. The market is expected to grow at a CAGR of 4.35% during the forecast period of 2025-2034, with the values likely to attain USD 7.56 Billion by 2034.
Ischemic Heart Disease Drugs Market Overview
Ischemic heart diseases are medical conditions under which the patient’s heart arteries that supply blood to the heart muscle get narrowed, lowering the blood flow. In severe cases, the patient suffers from artery blockage which is then treated surgically (if feasible). To improve the blood flow in such medical conditions, ischemic heart disease drugs are prescribed to patients. The market is expected to witness substantial growth due to the increasing prevalence of heart diseases worldwide. With the increasing prevalence, the increasing demand for ischemic heart disease drugs is corresponding.
Ischemic Heart Disease Drugs Market Growth Factors
Prevalence of Heart Diseases Boosting the Market Demand
The increasing prevalence of cardiovascular diseases is contributing to the increased demand for ischemic heart disease drugs. According to the new Global Burden of Disease (GBD) special report published in 2023, ischemic heart disease is the leading cause of death for cardiovascular disease worldwide. It causes 108.8 deaths per 100,000 people. Estimated by the Centers for Disease Control and Prevention nearly 805,000 people suffer from a heart attack every year in the United States. As a result, the demand for effective therapeutics is on the rise.
Rising Approvals by the Regulatory Authorities to Meet the Ischemic Heart Disease Drugs Market Demand
In March 2024, the U.S. Food and Drug Administration gave clearance to Wegovy (semaglutide) injection, expanding its use to reduce the risk of cardiovascular death, heart attack, and stroke in overweight or obese adults. This approval marks a significant advancement in the management of ischemic heart disease, particularly for patients at higher risk due to their weight. Wegovy is an established medication for weight management that is now additionally useful in the treatment of obesity with direct cardiovascular benefits, potentially transforming the therapeutic landscape for ischemic heart disease. The approval was based on a robust, multi-national, placebo-controlled double-blind trial involving over 17,600 participants, reinforcing the drug's efficacy and safety. This development is expected to drive increased adoption of Wegovy in cardiovascular risk management, leading to increased market penetration and potentially stimulating further research and development in cardio-metabolic drugs. Consequently, the ischemic heart disease drugs market is likely to witness significant growth, with enhanced treatment options that address both the symptoms of heart disease and risk factors such as obesity.
In December 2023, the FDA approved colchicine drug (traditionally used for gout and other inflammatory conditions) for the prevention of heart disease as well. Previously Lodoco, colchicine was approved recently to manage cholesterol levels, and blood pressure and reduce the risk of heart disease and stroke. This approval marked a significant expansion in the use of colchicine, positioning it as a potential drug in ischemic heart disease management. This approval could potentially trigger increased clinical research and investment for the repurposing of other existing drugs for cardiovascular indications, boosting the market growth.
Regulatory Authorities Expanding the Application of Drug
In March 2024, Regeneron Pharmaceuticals, Inc. announced that the U.S. Food & Drug Administration (FDA) has approved the expansion of Praluent® (alirocumab) usage to include pediatric patients aged 8 and older with heterozygous familial hypercholesterolemia (HeFH). This approval marks a significant expansion in the treatment landscape for ischemic heart disease, as Praluent, targeting the PCSK9 enzyme, becomes one of the few therapies available to younger patients at high genetic risk of heart disease. With the expanded usage of Praluent, it will now be helpful in treating heart disease in early diagnosis and effectively managing the condition in the long term. Consequently, the market is poised for substantial growth.
Ischemic Heart Disease Drugs Market Trends
Increasing Prevalence of Cardiovascular Diseases
The market is witnessing a growing geriatric population, susceptible to ischemic heart diseases. The increasing geriatric population is contributing to the increasing prevalence of the ischemic heart disease IHD worldwide.
Advancements in Drug Development
With increasing advancements in drug development, the market is witnessing a significant shift towards personalised medicine in the treatment of IHD.
Advent of Biologics and Novel Drugs Molecules
The market is experiencing a significant shift towards the development of biologics and novel small-molecule drugs offering innovative treatments.
Increasing Emphasis on Early Prevention
Increasing demand for medication that curbs or manages the occurrence of risk factors leading to IHDs is driving the market growth. The demand for blood pressure and cholesterol management drugs is consistent.
Ischemic Heart Disease Drugs Market Segmentation
The EMR’s report titled “Ischemic Heart Disease Drugs Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Type Germany
France
Italy
Spain
United Kingdom
Angina Pectoris Leads the Market Segmentation Based on Disease Type
The market share based on disease type includes angina pectoris and myocardial infarction. The angina pectoris segment is expected to lead the market due to its high prevalence. Angina is a symptom of coronary artery disease in which chest pain is experienced by the patient due to reduced blood flow to the heart muscles. Frequent encounters drive demand for drugs to provide relief and improve patient’s quality of life.
Market Segmentation Based on Drug Class to Witness Substantial Growth
The drug class segmentation includes anti-dyslipidemic drugs, calcium channel blockers, beta-blockers, ACE inhibitors, ARBs, vasodilators, and antithrombotic agents. The drug class segmentation is dominated by anti-dyslipidemic drugs as management of blood lipid levels is necessary to avoid and treat ischemic heart diseases (IHD). These drugs include statins, fibrates, and cholesterol absorption inhibitors that are considered effective in reducing cholesterol levels. It is particularly effective in managing bad cholesterol LDL, a major risk factor for the formation of plaques in the arteries.
Ischemic Heart Disease Drugs Market Analysis by Region
Based on the regions, the market report covers the United States, EU-4 (Germany, France, Italy, Spain) and the United Kingdom, Japan and India, with each region contributing to the overall dynamics of the market. United States is leading the market share with the presence of a robust healthcare infrastructure to provide high-end treatments to patients. The increasing prevalence of people suffering from heart diseases such as coronary artery disease (CAD), arrhythmias, cardiomyopathy, and valvular heart diseases, among others is collectively driving the demand for ischemic heart disease drugs in the region. Data from the Centers for Disease Control and Prevention states that in the United States, every 33 seconds cardiovascular disease claims a human life. The annual expenditure on heart disease amounted to USD 239.9 billion from 2018 to 2019.
Leading Players in the Ischemic Heart Disease Drugs Market
The key features of the market report include patent analysis, clinical trials analysis, grants, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Eli Lilly and Company
Eli Lilly and Company was established in 1876 and is currently headquartered in Indianapolis, Indiana, USA. The company is focused on developing and distributing effective medications for various including endocrinology, oncology, immunology, neuroscience, and cardiovascular diseases.
Bayer AG
Founded in 1863, Bayer AG is a prominent pharmaceutical company focused on cardiology, hematology and oncology related prescription drugs. Some notable products in the cardiovascular domain include aspirin, Xarelto (rivaroxaban), and Eylea (aflibercept) among others.
Pfizer Inc
Headquartered in New York, USA, this company was established in 1849. The company has a strong product portfolio of cardiovascular diseases as well as continuously takes part in research initiatives for providing a diverse range of medications to consumers.
Other players in the market include Sanofi, Novartis AG, Baxter International, Inc., Merck & Co., Inc., Johnson & JohnsonServices, Inc., Amgen Inc., Boehringer Ingelheim International GmbH
F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Bristol-Myers Squibb Company, and Eisai Co., Ltd.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Queries Solved in the Ischemic Heart Disease Drugs Market Report
Ischemic Heart Disease Drugs Market Overview
Ischemic heart diseases are medical conditions under which the patient’s heart arteries that supply blood to the heart muscle get narrowed, lowering the blood flow. In severe cases, the patient suffers from artery blockage which is then treated surgically (if feasible). To improve the blood flow in such medical conditions, ischemic heart disease drugs are prescribed to patients. The market is expected to witness substantial growth due to the increasing prevalence of heart diseases worldwide. With the increasing prevalence, the increasing demand for ischemic heart disease drugs is corresponding.
Ischemic Heart Disease Drugs Market Growth Factors
Prevalence of Heart Diseases Boosting the Market Demand
The increasing prevalence of cardiovascular diseases is contributing to the increased demand for ischemic heart disease drugs. According to the new Global Burden of Disease (GBD) special report published in 2023, ischemic heart disease is the leading cause of death for cardiovascular disease worldwide. It causes 108.8 deaths per 100,000 people. Estimated by the Centers for Disease Control and Prevention nearly 805,000 people suffer from a heart attack every year in the United States. As a result, the demand for effective therapeutics is on the rise.
Rising Approvals by the Regulatory Authorities to Meet the Ischemic Heart Disease Drugs Market Demand
In March 2024, the U.S. Food and Drug Administration gave clearance to Wegovy (semaglutide) injection, expanding its use to reduce the risk of cardiovascular death, heart attack, and stroke in overweight or obese adults. This approval marks a significant advancement in the management of ischemic heart disease, particularly for patients at higher risk due to their weight. Wegovy is an established medication for weight management that is now additionally useful in the treatment of obesity with direct cardiovascular benefits, potentially transforming the therapeutic landscape for ischemic heart disease. The approval was based on a robust, multi-national, placebo-controlled double-blind trial involving over 17,600 participants, reinforcing the drug's efficacy and safety. This development is expected to drive increased adoption of Wegovy in cardiovascular risk management, leading to increased market penetration and potentially stimulating further research and development in cardio-metabolic drugs. Consequently, the ischemic heart disease drugs market is likely to witness significant growth, with enhanced treatment options that address both the symptoms of heart disease and risk factors such as obesity.
In December 2023, the FDA approved colchicine drug (traditionally used for gout and other inflammatory conditions) for the prevention of heart disease as well. Previously Lodoco, colchicine was approved recently to manage cholesterol levels, and blood pressure and reduce the risk of heart disease and stroke. This approval marked a significant expansion in the use of colchicine, positioning it as a potential drug in ischemic heart disease management. This approval could potentially trigger increased clinical research and investment for the repurposing of other existing drugs for cardiovascular indications, boosting the market growth.
Regulatory Authorities Expanding the Application of Drug
In March 2024, Regeneron Pharmaceuticals, Inc. announced that the U.S. Food & Drug Administration (FDA) has approved the expansion of Praluent® (alirocumab) usage to include pediatric patients aged 8 and older with heterozygous familial hypercholesterolemia (HeFH). This approval marks a significant expansion in the treatment landscape for ischemic heart disease, as Praluent, targeting the PCSK9 enzyme, becomes one of the few therapies available to younger patients at high genetic risk of heart disease. With the expanded usage of Praluent, it will now be helpful in treating heart disease in early diagnosis and effectively managing the condition in the long term. Consequently, the market is poised for substantial growth.
Ischemic Heart Disease Drugs Market Trends
Increasing Prevalence of Cardiovascular Diseases
The market is witnessing a growing geriatric population, susceptible to ischemic heart diseases. The increasing geriatric population is contributing to the increasing prevalence of the ischemic heart disease IHD worldwide.
Advancements in Drug Development
With increasing advancements in drug development, the market is witnessing a significant shift towards personalised medicine in the treatment of IHD.
Advent of Biologics and Novel Drugs Molecules
The market is experiencing a significant shift towards the development of biologics and novel small-molecule drugs offering innovative treatments.
Increasing Emphasis on Early Prevention
Increasing demand for medication that curbs or manages the occurrence of risk factors leading to IHDs is driving the market growth. The demand for blood pressure and cholesterol management drugs is consistent.
Ischemic Heart Disease Drugs Market Segmentation
The EMR’s report titled “Ischemic Heart Disease Drugs Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Type
- Angina Pectoris
- Myocardial Infarction
- Anti-Dyslipidemic Drugs
- Calcium Channel Blockers
- Beta-Blockers
- ACE Inhibitors
- ARBs
- Vasodilators
- Antithrombotic Agents
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- United States
- EU-4 and the United Kingdom
- Japan
- India
Angina Pectoris Leads the Market Segmentation Based on Disease Type
The market share based on disease type includes angina pectoris and myocardial infarction. The angina pectoris segment is expected to lead the market due to its high prevalence. Angina is a symptom of coronary artery disease in which chest pain is experienced by the patient due to reduced blood flow to the heart muscles. Frequent encounters drive demand for drugs to provide relief and improve patient’s quality of life.
Market Segmentation Based on Drug Class to Witness Substantial Growth
The drug class segmentation includes anti-dyslipidemic drugs, calcium channel blockers, beta-blockers, ACE inhibitors, ARBs, vasodilators, and antithrombotic agents. The drug class segmentation is dominated by anti-dyslipidemic drugs as management of blood lipid levels is necessary to avoid and treat ischemic heart diseases (IHD). These drugs include statins, fibrates, and cholesterol absorption inhibitors that are considered effective in reducing cholesterol levels. It is particularly effective in managing bad cholesterol LDL, a major risk factor for the formation of plaques in the arteries.
Ischemic Heart Disease Drugs Market Analysis by Region
Based on the regions, the market report covers the United States, EU-4 (Germany, France, Italy, Spain) and the United Kingdom, Japan and India, with each region contributing to the overall dynamics of the market. United States is leading the market share with the presence of a robust healthcare infrastructure to provide high-end treatments to patients. The increasing prevalence of people suffering from heart diseases such as coronary artery disease (CAD), arrhythmias, cardiomyopathy, and valvular heart diseases, among others is collectively driving the demand for ischemic heart disease drugs in the region. Data from the Centers for Disease Control and Prevention states that in the United States, every 33 seconds cardiovascular disease claims a human life. The annual expenditure on heart disease amounted to USD 239.9 billion from 2018 to 2019.
Leading Players in the Ischemic Heart Disease Drugs Market
The key features of the market report include patent analysis, clinical trials analysis, grants, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Eli Lilly and Company
Eli Lilly and Company was established in 1876 and is currently headquartered in Indianapolis, Indiana, USA. The company is focused on developing and distributing effective medications for various including endocrinology, oncology, immunology, neuroscience, and cardiovascular diseases.
Bayer AG
Founded in 1863, Bayer AG is a prominent pharmaceutical company focused on cardiology, hematology and oncology related prescription drugs. Some notable products in the cardiovascular domain include aspirin, Xarelto (rivaroxaban), and Eylea (aflibercept) among others.
Pfizer Inc
Headquartered in New York, USA, this company was established in 1849. The company has a strong product portfolio of cardiovascular diseases as well as continuously takes part in research initiatives for providing a diverse range of medications to consumers.
Other players in the market include Sanofi, Novartis AG, Baxter International, Inc., Merck & Co., Inc., Johnson & JohnsonServices, Inc., Amgen Inc., Boehringer Ingelheim International GmbH
F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Bristol-Myers Squibb Company, and Eisai Co., Ltd.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Queries Solved in the Ischemic Heart Disease Drugs Market Report
- What was the ischemic heart disease drugs market value in 2024?
- What is the ischemic heart disease drugs market forecast outlook for 2025-2034?
- What are the major factors aiding the global market demand?
- What are the major market trends?
- What is the market segmentation based on the disease type?
- What is the market segmentation based on the distribution channel?
- What is the market breakup by drug class?
- What are the major markets according to the EMR report?
- Who are the key players involved in the ischemic heart disease drugs market?
- How will the market landscape evolve in the upcoming years?
- What are the major drivers, opportunities, and restraints in the market?
- What will be the effect of each driver, challenge, and opportunity on the market?
- Which country is poised to lead the market share in the forecast period?
- Which segment has the highest impact on the market size?
- How are partnerships, collaborations, mergers and acquisitions shaping the market dynamics?
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Ischemic Heart Disease Drugs Market Overview: 8 Major Market
- 3.1 Ischemic Heart Disease Drugs Market Historical Value (2018-2024)
- 3.2 Ischemic Heart Disease Drugs Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Ischemic Heart: Disease Drugs Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Therapy Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Therapy Success Rate
- 7 Ischemic Heart Disease Market Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 U.S.
- 7.1.1.2 U.K.
- 7.1.1.3 EU4
- 7.1.1.4 India
- 7.1.1.5 Japan
- 7.1.2 Mortality by Country
- 7.1.2.1 U.S.
- 7.1.2.2 U.K.
- 7.1.2.3 EU4
- 7.1.2.4 India
- 7.1.2.5 Japan
- 7.1.3 Treatment Seeking Rate by Country
- 7.1.3.1 U.S.
- 7.1.3.2 U.K.
- 7.1.3.3 EU4
- 7.1.3.4 India
- 7.1.3.5 Japan
- 8 Ischemic Heart Disease Drugs Market Landscape: 8 Major Market*
- 8.1 Ischemic Heart Disease Drugs Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Ischemic Heart Disease Drugs Market: Product Landscape
- 8.2.1 Analysis by Disease
- 8.2.2 Analysis by Drug Class
- 9 Ischemic Heart Disease Drugs Market Therapy Challenges and Unmet Needs
- 9.1 Therapy Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Therapy
- 11 Ischemic Heart Disease Drugs: Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Ischemic Heart Disease Drugs Market Segmentation: 8 Major Market
- 12.1 Ischemic Heart Disease Drugs Market (2018-2034) by Disease
- 12.1.1 Market Overview
- 12.1.2 Angina Pectoris
- 12.1.3 Myocardial Infarction
- 12.2 Ischemic Heart Disease Drugs Market (2018-2034) by Drug Class
- 12.2.1 Market Overview
- 12.2.2 Anti-Dyslipidemic Drugs
- 12.2.3 Calcium Channel Blockers
- 12.2.4 Beta-Blockers
- 12.2.5 ACE Inhibitors
- 12.2.6 ARBs
- 12.2.7 Vasodilators
- 12.2.8 Antithrombotic Agents
- 12.3 Ischemic Heart Disease Drugs Market by Distribution Channel
- 12.3.1 Market Overview
- 12.3.2 Hospital Pharmacy
- 12.3.3 Retail Pharmacy
- 12.3.4 Online Pharmacy
- 12.4 Ischemic Heart Disease Drugs Market by Region
- 12.4.1 Market Overview
- 12.4.2 United States
- 12.4.3 EU-4 and the United Kingdom
- 12.4.3.1 Germany
- 12.4.3.2 France
- 12.4.3.3 Italy
- 12.4.3.4 Spain
- 12.4.3.5 United Kingdom
- 12.4.4 Japan
- 12.4.5 India
- 13 United States Ischemic Heart Disease Drugs Market (218-2034)
- 13.1 United States Ischemic Heart Disease Drugs Market Historical Value (2018-2024)
- 13.2 United States Ischemic Heart Disease Drugs Market Forecast Value (2025-2034)
- 13.3 United States Ischemic Heart Disease Drugs Market (2018-2034) by Disease
- 13.3.1 Market Overview
- 13.3.2 Angina Pectoris
- 13.3.3 Myocardial Infarction
- 13.4 United States Ischemic Heart Disease Drugs Market (2018-2034) by Drug Class
- 13.4.1 Market Overview
- 13.4.2 Anti-Dyslipidemic Drugs
- 13.4.3 Calcium Channel Blockers
- 13.4.4 Beta-Blockers
- 13.4.5 ACE Inhibitors
- 13.4.6 ARBs
- 13.4.7 Vasodilators
- 13.4.8 Antithrombotic Agents
- 14 EU-4 and United Kingdom Ischemic Heart Disease Drugs Market (218-2034)
- 14.1 EU-4 and United Kingdom Ischemic Heart Disease Drugs Market Historical Value (2018-2024)
- 14.2 EU-4 and United Kingdom Ischemic Heart Disease Drugs Market Forecast Value (2025-2034)
- 14.3 EU-4 and United Kingdom Ischemic Heart Disease Drugs Market (2018-2034) by Disease
- 14.3.1 Market Overview
- 14.3.2 Angina Pectoris
- 14.3.3 Myocardial Infarction
- 14.4 EU-4 and United Kingdom Ischemic Heart Disease Drugs Market (2018-2034) by Drug Class
- 14.4.1 Market Overview
- 14.4.2 Anti-Dyslipidemic Drugs
- 14.4.3 Calcium Channel Blockers
- 14.4.4 Beta-Blockers
- 14.4.5 ACE Inhibitors
- 14.4.6 ARBs
- 14.4.7 Vasodilators
- 14.4.8 Antithrombotic Agents
- 15 Japan Ischemic Heart Disease Drugs Drugs Market
- 15.1 Japan Ischemic Heart Disease Drugs Market Historical Value (2018-2024)
- 15.2 Japan Ischemic Heart Disease Drugs Market Forecast Value (2025-2034)
- 15.3 Japan Ischemic Heart Disease Drugs Market (2018-2034) by Disease
- 15.3.1 Market Overview
- 15.3.2 Angina Pectoris
- 15.3.3 Myocardial Infarction
- 15.4 Japan Ischemic Heart Disease Drugs Market (2018-2034) by Drug Class
- 15.4.1 Market Overview
- 15.4.2 Anti-Dyslipidemic Drugs
- 15.4.3 Calcium Channel Blockers
- 15.4.4 Beta-Blockers
- 15.4.5 ACE Inhibitors
- 15.4.6 ARBs
- 15.4.7 Vasodilators
- 15.4.8 Antithrombotic Agents
- 16 India Ischemic Heart Disease Drugs Drugs Market
- 16.1 India Ischemic Heart Disease Drugs Market (2018-2034) Historical Value (2018-2024)
- 16.2 India Ischemic Heart Disease Drugs Market (2018-2034) Forecast Value (2025-2034)
- 16.3 India Ischemic Heart Disease Drugs Market (2018-2034) by Disease
- 16.3.1 Market Overview
- 16.3.2 Angina Pectoris
- 16.3.3 Myocardial Infarction
- 16.4 India Ischemic Heart Disease Drugs Market (2018-2034) by Drug Class
- 16.4.1 Market Overview
- 16.4.2 Anti-Dyslipidemic Drugs
- 16.4.3 Calcium Channel Blockers
- 16.4.4 Beta-Blockers
- 16.4.5 ACE Inhibitors
- 16.4.6 ARBs
- 16.4.7 Vasodilators
- 16.4.8 Antithrombotic Agents
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 INDIA CDSCO
- 17.5 JAPAN PMDA
- 17.6 Others
- 18 Patent Analysis
- 18.1 Analysis by Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 18.7 Analysis by Key Players
- 19 Clinical Trial Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Grant Analysis
- 20.1 Analysis by Year
- 20.2 Analysis by Amount Awarded
- 20.3 Analysis by Issuing Authority
- 20.4 Analysis by Grant Product
- 20.5 Analysis by Funding Institute
- 20.6 Analysis by Departments
- 20.7 Analysis by Recipient Organization
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Type of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Strategic Initiatives
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Type of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share by Top 5 Companies
- 23.2 Eli Lilly and Company
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Mergers and Acquisitions
- 23.2.5 Certifications
- 23.3 Bayer AG
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Mergers and Acquisitions
- 23.3.5 Certifications
- 23.4 Pfizer, Inc.
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Mergers and Acquisitions
- 23.4.5 Certifications
- 23.5 Sanofi S.A.
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Mergers and Acquisitions
- 23.5.5 Certifications
- 23.6 Novartis AG
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Mergers and Acquisitions
- 23.6.5 Certifications
- 23.7 Baxter International, Inc.
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Mergers and Acquisitions
- 23.7.5 Certifications
- 23.8 Merck & Co., Inc.
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Mergers and Acquisitions
- 23.8.5 Certifications
- 23.9 Johnson & Johnson Services, Inc.
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Mergers and Acquisitions
- 23.9.5 Certifications
- 23.10 Amgen Inc.
- 23.10.1 Financial Analysis
- 23.10.2 Product Portfolio
- 23.10.3 Demographic
- 23.10.4 Mergers and Acquisitions
- 23.10.5 Certifications
- 23.11 Boehringer Ingelheim International GmbH
- 23.11.1 Financial Analysis
- 23.11.2 Product Portfolio
- 23.11.3 Demographic Reach and Achievements
- 23.11.4 Mergers and Acquisitions
- 23.11.5 Certifications
- 23.12 F. Hoffmann-La Roche AG
- 23.12.1 Financial Analysis
- 23.12.2 Product Portfolio
- 23.12.3 Demographic Reach and Achievements
- 23.12.4 Mergers and Acquisitions
- 23.12.5 Certifications
- 23.13 GlaxoSmithKline plc
- 23.13.1 Financial Analysis
- 23.13.2 Product Portfolio
- 23.13.3 Demographic Reach and Achievements
- 23.13.4 Mergers and Acquisitions
- 23.13.5 Certifications
- 23.14 Bristol-Myers Squibb Company
- 23.14.1 Financial Analysis
- 23.14.2 Product Portfolio
- 23.14.3 Demographic Reach and Achievements
- 23.14.4 Mergers and Acquisitions
- 23.14.5 Certifications
- 23.15 Eisai Co., Ltd.
- 23.15.1 Financial Analysis
- 23.15.2 Product Portfolio
- 23.15.3 Demographic Reach and Achievements
- 23.15.4 Mergers and Acquisitions
- 23.15.5 Certifications
- 24 Ischemic Heart Disease Drugs Market – Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
